Invivogen
Menu

Anti-dCD20c1-mIgG2a

Anti-dCD20c1-mIgG2a Unit size Cat. code Docs Qty Price
Monoclonal mouse IgG2a antibody against dog CD20
100 µg
dcd20-mab11
+-
$258.00

Monoclonal mouse IgG2a antibody against dog CD20

Anti-dCD20c1-mIgG2a is a mouse monoclonal antibody that specifically targets dog CD20 (dCD20).
In flow cytometry applications, this antibody has exhibited weak cross-reactivity with human CD20. Reactivity with other species has not been tested.

Anti-dCD20c1-mIgG2a was generated by DNA immunization.

This antibody has been screened for the ability to bind dCD20 and induce complement-dependent cytotoxicity (CDC). It is produced by hybridoma cells and purified by affinity chromatography with protein A.

This antibody is not suitable for immunohistochemical staining.

Back to the top

Specifications

Clonality: Monoclonal antibody.

Specificity: Targets cells expressing dog CD20.

Isotype: Mouse IgG2a.

Clone: 6C12.

Formulation: 0.2 µm filtered solution in 68 mM phosphate buffer with 91 mM glycine, 5% w/v saccharose and stabilizing agents.

Quality control:

  • The absence of bacterial contamination (e.g. endotoxins and peptidoglycans) is confirmed by using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
  • The antibody is validated for flow cytometry using cells that stably express dog CD20.

Applications : B-cell depletion, Flow Cytometry.

Back to the top

Contents

100 µg purified anti-dCD20c1-mIgG2a antibody, provided azide-free and lyophilized.

Product is shipped at room temperature.

Store lyophilized antibody at -20°C.

Back to the top

Description

CD20 is a transmembrane phosphoprotein that is expressed on the surface of B lymphocytes. The CD20 antigen is present on both resting and activated B lymphocytes but is lost prior to differentiation into plasma cells.

As CD20 expression is restricted to B cells, this antigen is a useful marker or target for B-cell lymphomas [1]. Studies demonstrate that the expression of CD20 correlates with B-cell lymphoma in dogs [2]. In human medicine, an anti-human CD20 monoclonal antibody (Rituximab) has been approved by the FDA to treat B-cell non-Hodgkin's lymphoma resistant to other chemotherapy regimens.

This antibody was tested for B-cell binding and depletion in canine B-cells ex vivo; however, this human therapeutic is not able to bind or deplete canine B-cells [3, 4]. Thus, there is a need for specific antibodies directed against dog CD20. Such antibodies can be used to investigate CD20 as a therapeutic target in canine lymphoma.

1. Kosmas C. et al., 2002. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia. 16(10):2004-15.
2. Jubala C. et al., 2005. CD20 Expression in Normal Canine B Cells and in Canine non-Hodgkin Lymphoma. Vet. Path. 42:468-76.
3. Crow S., 2008. Chemoimmunotherapy for canine lymphoma: tumor vaccines and monoclonal antibodies. Cancer Therapy 6;181-6.
4. Impellizeri J. et al., 2006. The role of rituximab in the treatment of canine lymphoma: An ex vivo evaluation. Vet. J. 171:556-8.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty